Home›Stock Screener›Astal Laboratories›Financial Statements

Astal Laboratories Complete Financial Statements

12 Years of Data
2026 - 2015

In FY2026, Astal Laboratories (ASTALLTD) reported revenue ₹134 Cr, net profit ₹8 Cr and EPS ₹0.29, with a net profit margin of 6.0% and ROE of 2.4%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see ASTALLTD screener.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 5.97% 2026 data
EBITDA Margin 7.46% 2026 data
Operating Margin 8.00% 2026 data
Return on Assets 2.00% 2026 data
Return on Equity 2.45% 2026 data

Balance Sheet Ratios

Current Ratio 103.00 2026 data
Equity Ratio 81.75% 2026 data
Asset Turnover 0.34 2026 data

ASTALLTD Revenue, Net Profit & EBITDA — Year-on-Year Growth

ASTALLTD YoY (Mar 2025 vs Mar 2026) — revenue +458.3%, net profit +166.7%, EBITDA +150.0%, expenses +552.6%. Explore Astal Laboratories intrinsic worth to estimate fundamental worth using multiple valuation models.

Revenue Growth
+458.3%
Year-over-Year
Net Profit Growth
+166.7%
Year-over-Year
EBITDA Growth
+150.0%
Year-over-Year
Expense Growth
+552.6%
Year-over-Year
Assets Growth
+534.9%
Year-over-Year
Equity Growth
+808.3%
Year-over-Year
Operating Cash Flow Growth
-116.7%
Year-over-Year
Investing Cash Flow Growth
-33.3%
Year-over-Year
Financing Cash Flow Growth
-83.3%
Year-over-Year

ASTALLTD Income Statement — Revenue, EBITDA & Net Profit

Astal Laboratories revenue ₹134 Cr, EBITDA ₹10 Cr, net profit ₹8 Cr, EPS ₹0.29 (2026) — net profit margin 6.0%. Review ASTALLTD PE ratio trends to evaluate earnings-based valuation against sector peers.

Periods ₹ Crores
Particulars Mar 2026 Mar 2025 Dec 2025
Revenue 134 24 52
Expenses 124 19 49
EBITDA 10 4 4
Operating Profit Margin % 8.00% 18.00% 7.00%
Depreciation 1 0 0
Interest 1 0 0
Profit Before Tax 8 4 3
Tax 1 1 1
Net Profit 8 3 2
Earnings Per Share (₹) 0.29 2.80 2.19

ASTALLTD Balance Sheet — Assets, Liabilities & Shareholders' Equity

ASTALLTD total assets ₹400 Cr, total equity ₹327 Cr, total liabilities ₹ Cr (2026) — ROE 2.4%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 400 63 37 10 5 5 5 5 5 5 5 5
Current Assets 103 46 27 6 0 0 5 5 5 5 5 5
Fixed Assets 12 11 1 0 0 0 0 0 0 0 0 0
Capital Work in Progress 0 0 0 0 0 0 0 0 0 0 0 0
Investments 29 0 0 0 0 0 0 0 0 0 0 0
Other Assets 0 52 36 10 5 5 5 5 5 5 5 5
LIABILITIES
Total Liabilities
Current Liabilities 1 1 0 0 0 0 0 0 0 0 0 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 327 36 23 5 5 5 5 5 5 5 5 5
Share Capital 42 10 10 4 4 4 4 4 4 4 4 4
Reserves & Surplus 285 22 14 1 1 1 1 1 1 1 1 1

ASTALLTD Cash Flow Statement — Operating, Investing & Financing

Astal Laboratories operating cash flow ₹-13 Cr, investing ₹-8 Cr, financing ₹3 Cr, net cash flow ₹-17 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities -13 -6 -1 0 0 0 0 0 0 0 0
Investing Activities -8 -6 2 0 0 0 0 0 0 0 0
Financing Activities 3 18 0 0 0 0 0 0 0 0 0
Net Cash Flow -17 6 0 0 0 0 0 0 0 0 0